Literature DB >> 27061154

Impact of incident myocardial infarction on the risk of venous thromboembolism: the Tromsø Study.

L B Rinde1, C Lind1, B Småbrekke1, I Njølstad1,2, E B Mathiesen1,3, T Wilsgaard2, M-L Løchen2, E M Hald1,4, A Vik1,4, S K Braekkan1,4, J-B Hansen1,4.   

Abstract

UNLABELLED: Essentials Registry-based studies indicate a link between arterial- and venous thromboembolism (VTE). We studied this association in a cohort with confounder information and validated outcomes. Myocardial infarction (MI) was associated with a 4.8-fold increased short-term risk of VTE. MI was associated with a transient increased risk of VTE, and pulmonary embolism in particular.
SUMMARY: Background Recent studies have demonstrated an association between venous thromboembolism (VTE) and arterial thrombotic diseases. Objectives To study the association between incident myocardial infarction (MI) and VTE in a prospective population-based cohort. Methods Study participants (n = 29 506) were recruited from three surveys of the Tromsø Study (conducted in 1994-1995, 2001-2002, and 2007-2008) and followed up to 2010. All incident MI and VTE events during follow-up were recorded. Cox regression models with age as the time scale and MI as a time-dependent variable were used to calculate hazard ratios (HRs) of VTE adjusted for sex, body mass index, blood pressure, diabetes mellitus, HDL cholesterol, smoking, physical activity, and education level. Results During a median follow-up of 15.7 years, 1853 participants experienced an MI and 699 experienced a VTE. MI was associated with a 51% increased risk of VTE (HR 1.51; 95% confidence interval [CI] 1.08-2.10) and a 72% increased risk of pulmonary embolism (PE) (HR 1.72; 95% CI 1.07-2.75), but not significantly associated with the risk of deep vein thrombosis (DVT) (HR 1.36; 95% CI 0.86-2.15). The highest risk estimates for PE were observed during the first 6 months after the MI (HR 8.49; 95% CI 4.00-18.77). MI explained 6.2% of the PEs in the population (population attributable risk) and 78.5% of the PE risk in MI patients (attributable risk). Conclusions Our findings indicate that MI is associated with a transient increased VTE risk, independently of traditional atherosclerotic risk factors. The risk estimates were particularly high for PE.
© 2016 International Society on Thrombosis and Haemostasis.

Entities:  

Keywords:  epidemiology; myocardial infarction; pulmonary embolism; risk factors; venous thromboembolism

Mesh:

Year:  2016        PMID: 27061154     DOI: 10.1111/jth.13329

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  7 in total

1.  Pulmonary embolism and deep vein thrombosis-comorbidities and temporary provoking factors in a register-based study of 1.48 million people.

Authors:  Katarina Glise Sandblad; Annika Rosengren; Jan Sörbo; Sverker Jern; Per-Olof Hansson
Journal:  Res Pract Thromb Haemost       Date:  2022-06-03

2.  Metabolic Syndrome Increases Risk of Venous Thromboembolism Recurrence after Acute Pulmonary Embolism.

Authors:  Lauren K Stewart; Jeffrey A Kline
Journal:  Ann Am Thorac Soc       Date:  2020-07

3.  Atherosclerotic Risk Factors and Risk of Myocardial Infarction and Venous Thromboembolism; Time-Fixed versus Time-Varying Analyses. The Tromsø Study.

Authors:  Birgit Småbrekke; Ludvig Balteskard Rinde; Kristian Hindberg; Erin Mathiesen Hald; Anders Vik; Tom Wilsgaard; Maja-Lisa Løchen; Inger Njølstad; Ellisiv B Mathiesen; John-Bjarne Hansen; Sigrid Brækkan
Journal:  PLoS One       Date:  2016-09-16       Impact factor: 3.240

4.  Venous thromboembolism in patients hospitalized for knee joint replacement surgery.

Authors:  Karsten Keller; Lukas Hobohm; Stefano Barco; Irene Schmidtmann; Thomas Münzel; Martin Engelhardt; Lukas Eckhard; Stavros V Konstantinides; Philipp Drees
Journal:  Sci Rep       Date:  2020-12-31       Impact factor: 4.379

5.  Plasma lipopolysaccharide-binding protein is a biomarker for future venous thromboembolism: Results from discovery and validation studies.

Authors:  Søren Beck Jensen; Nadezhda Latysheva; Kristian Hindberg; Thor Ueland
Journal:  J Intern Med       Date:  2022-04-27       Impact factor: 13.068

6.  Myocardial infarction, prothrombotic genotypes, and venous thrombosis risk: The Tromsø Study.

Authors:  Joakim K Sejrup; Vania M Morelli; Maja-Lisa Løchen; Inger Njølstad; Ellisiv B Mathiesen; Tom Wilsgaard; John-Bjarne Hansen; Sigrid K Brækkan
Journal:  Res Pract Thromb Haemost       Date:  2020-01-27

7.  Serum amyloid A4 is a procoagulant apolipoprotein that it is elevated in venous thrombosis patients.

Authors:  José A Fernández; Hiroshi Deguchi; Darlene J Elias; John H Griffin
Journal:  Res Pract Thromb Haemost       Date:  2019-12-29
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.